ArticleCureus2025
Utility of Small Bowel Capsule Endoscopy and Leucine-Rich Alpha-2-Glycoprotein in Pediatric Crohn's Disease Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Mucosal remission is a key treatment goal for Crohn's disease (CD). Small-bowel capsule endoscopy (SBCE) is a minimally invasive modality for evaluating small-bowel mucosa; however, standardized criteria for mucosal remission have not yet been established. This study aimed to investigate the correlation and comparative sensitivity of the Lewis score (LS) and Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) in assessing small-bowel inflammation in pediatric Crohn's disease (CD) and to evaluate biomarkers as predictors of small bowel mucosal remission. Methods This cohort study included pediatric patients with CD at a single center in Japan. Demographics, clinical symptoms, serum C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), and leucine-rich alpha-2 glycoprotein (LRG) levels were evaluated. SBCE findings were scored using LS and CECDAI. Results Among 26 patients, 54 SBCEs were performed, as some patients underwent multiple examinations. Median LS and CECDAI scores were 403 and 12, respectively. LS and CECDAI showed positive correlation (ρ = 0.82, p < 0.001). LS values of 135 and 790 corresponded to CECDAI of 7.1 and 16.5, respectively. Among 32 clinical remission cases, 24 had LS ≥ 135, while 17 had CECDAI ≥ 7.1. CRP, ESR and LRG correlated with SBCE findings, with LRG showing the strongest association (ρ = 0.74, p = 0.01). LRG < 13.4 µg/mL predicted small bowel mucosal remission. Conclusions LS and CECDAI showed a strong correlation, supporting their utility in evaluating small bowel inflammation in pediatric Crohn's disease. LS may have a tendency to detect milder or subclinical inflammatory changes, although the magnitude of this difference should be interpreted cautiously. In addition, LRG < 13.4 µg/mL strongly predicted mucosal remission, and these findings, though limited by sample size, suggest that LRG combined with clinical indices could serve as a noninvasive adjunct for timing SBCE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.